期刊文献+

以多西他赛为主联合沙利度胺治疗激素抵抗性前列腺癌的临床观察 被引量:3

下载PDF
导出
摘要 目的:观察以多西他赛为主联合沙利度胺治疗激素抵抗性前列腺癌的疗效及不良反应。方法:26例激素抵抗性前列腺癌患者,采用多西他赛75mg/m2,静脉滴注60分钟,d1,强的松5mg/次,1日2次,d1-21,每3周为1周期,沙利度胺适量服用。治疗2周期后评价疗效及不良反应。结果:26例均可评价疗效,共完成周期数为88个,完全缓解(CR)5例,部分缓解(PR)8例,稳定(SD)5例,进展(PD)8例,总有效率(CR+PR)50.0﹪,疾病控制率(CR+PR+SD)69.2%。中位疾病进展时间10.1个月,中位生存期为18.3个月(8.5-32.7个月)。主要不良反应为骨髓抑制、胃肠道反应。结论:以多西他赛为主联合沙利度胺治疗激素抵抗性前列腺癌疗效较好,毒副反应轻,耐受性好,值得临床推广。
机构地区 安阳市肿瘤医院
出处 《医学信息(中旬刊)》 2011年第7期3086-3087,共2页 Medical Information Operations Sciences Fascicule
  • 相关文献

参考文献10

  • 1王于勇(综述),郑祥毅(综述),谢立平(审校).激素抵抗性前列腺癌的治疗新进展[J].国际泌尿系统杂志,2007,27(6):754-756. 被引量:3
  • 2叶定伟,孙燕.激素抵抗性前列腺癌的治疗进展[J].中国癌症杂志,2007,17(3):220-224. 被引量:9
  • 3Kenyon BM. Effects of thalidomide and related metabolites in a mouse comeal of nevoscularization[ J]. Exp Eye Res, 1997,64:971. 被引量:1
  • 4Or R. Thalidomidc reduces vascular density in granulationtissue of subcuta- neously implantsd polyvingyl alcohol pongees in guinea pigs [ J ]. Exp He- matol, 1998,26 : 217. 被引量:1
  • 5Petfioli R, Paolelh L, Franeini E, et al. Weekly docetaxel and epiru - bicin in treatment of advanced hormone - refractory prostate cancer. Urology, 2007,69( 1 ) :142 - 146. 被引量:1
  • 6Engels FK, Verweij J. Docetaxel administration schedule: From feverto tears? A review of randomized studies. Eur J Cancer, 2005,41:1117 - 1126. 被引量:1
  • 7Petrylak DP. The treatment of horm one - refractory prostate cancer: do- cetaxel and beyond. Reviews in urology,2006,8(2) :48 -55. 被引量:1
  • 8Tannock IF,deWit R,Berry WJ,et al. Doeetaxel plus predni -soue or ml- toxantrone plus prednisone for advanced prostate cancer[ J]. bl Engl J Med, 2004,351:1502 - 1512. 被引量:1
  • 9Marriott J B, Clarke I A, Dredge K. Thalidomide and itaanalogues have dis- tinct and opposing efects on TNF - alpha and TNFR2 during co - stimula- tion of both CD( + ) and CDB( + ) Teells - 1. Clin Exp Immunol,2002, 130(1) .75 -84. 被引量:1
  • 10徐光辉,李玉,张为民.沙利度胺联合化疗治疗晚期胃癌的临床观察[J].临床肿瘤学杂志,2008,13(11):1012-1014. 被引量:5

二级参考文献21

  • 1秦自科,杨光伟,周芳坚,韩辉,刘卓炜,周宁宁,吴志刚.健择加顺铂全身化疗治疗激素非依赖性晚期前列腺癌的近期疗效[J].癌症,2004,23(12):1700-1703. 被引量:1
  • 2Jemal A, Siegel R,Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin ,2007,57( 1 ) : 43 -66. 被引量:1
  • 3Sonpavde G. , Hutson TE. New approaches in hormone refractory prostate cancer. Am J Clin 0ncol,2006,29 ( 2 ) : 196 - 201. 被引量:1
  • 4Armstrong A J, Febbo PG. Systemic strategies for prostate cancer. Minerva Urol Nefrol,2007,59 ( 1 ) : 11 - 25. 被引量:1
  • 5Hadaschik BA, Sowery RD, Gleave ME,et al. Novel targets and approaches in advanced prostate cancer. Curr Opin Urol,2007,17 (3) : 182 - 187. 被引量:1
  • 6Petrioli R,Panlelli L, Francini E,et al. Weekly docetaxel and epirubicin in treatment of advanced hormone - refractory prostate cancer. Urelogy,2007 ,69( 1 ) :142 - 146. 被引量:1
  • 7Engels FK, Verweij J. Docetaxel administration schedule: From fever to tears? A review of randomized studies. Eur J Cancer ,2005,41: 1117 -1126. 被引量:1
  • 8Petrylak DP. The treatment of hormone - refractory prostate cancer: docetaxel and beyond. Reviews in urology, 2006,8(2) : 48 -55. 被引量:1
  • 9Numata K, Miura N, Azuma K, et al. Oral estramustine phosphate and oral etoposide for the treatment of hormone - refractory prostate cancer. Hinyokika Kiyo,2007 ,53(2) :99 - 104. 被引量:1
  • 10Di Lorenzo G, De Placido S. Hormone refractory prostate cancer (HRPC) : present and future approaches of therapy. Int J Immunopathol Pharmacol. ,2006 , 19( 1 ) : 11 - 34. 被引量:1

共引文献13

同被引文献17

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部